All News
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
The greater the PsAID score, the more likely escalation in PsA treatment. Noted significant correlation between PsAID and physician global scores. Do you use PsAID in your clinic? Abs 1028 #ACR22 @RheumNow https://t.co/gcjm2XgPE3 https://t.co/bKPtXz5Nw8
Dr. Rachel Tate uptoTate ( View Tweet)
Abstr #1494 determinants of clinically important worsening (CIW) of early axSpA
- CIW = ASDAS ↑ > 0.9 b/w 2 visits
- Tender Joint count and ASAS-NSAID score associated w/ CIW
- MRI SI Jt inflammation & structural damage predictive of CIW
@RheumNow #ACR22 https://t.co/Dgeh25BaWM
Akhil Sood MD AkhilSoodMD ( View Tweet)
Global survey of rheumatic irAE people (me included)
Standard case
Variable answers, broadly distributed
none are wrong
We'll move from expert extrapolation of concepts to data-driven answers, with the right foundations👍
ABST0776 @MDAndersonNews @msalmazor #ACR22 @RheumNow https://t.co/5gMzWuCXd7
David Liew drdavidliew ( View Tweet)
Do patients with PsA like online wellness programs? #ACR22 @RheumNow
🌈 186 patients, 86% women, 90% White
🌈sleep and nutrition were highly rated for wellness
🌈cost and fatigue barriers to adopting wellness behaviors
🌈 27% were open to an online wellness program
Catherine Sims, MD DrCassySims ( View Tweet)
BASDAI and ASDAS performed similarly in axPsA pts, both demonstrating weak correlations w/ peripheral arthritis and moderate/strong correlations w/ pt fatigue and pain. Abs 1037 #ACR22 @RheumNow https://t.co/WRQx1hkIll https://t.co/kJVIWyVv2w
Dr. Rachel Tate uptoTate ( View Tweet)
3 yr interim RELIANCE study analysis shows long-term CAN tx is safe and effective in CAPS regardless of the underlying mutation and TRAPS. Abs 0812 #ACR22 @RheumNow https://t.co/pgSq1IICJK and https://t.co/Y2NUpgXGPL https://t.co/j9DMFF7V8S
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In clinic US guided entheseal biopsy? Abs 1025 at #ACR22 recommends the lateral epicondyle tendon plate in PsA pts. @RheumNow https://t.co/VomyFkecLq
Dr. Rachel Tate uptoTate ( View Tweet)
Exposure to DMARDs prior to ICI treatment was not associated with 2-year crude mortality rates. Abs 0764 #ACR22 @RheumNow https://t.co/WvTy84Si7u https://t.co/X4RvYAVSMC
Dr. Rachel Tate uptoTate ( View Tweet)
Window of opportunity in PsA
CorEvitas registry:
Early initiators had more severe disease & worse PROs
but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI
https://t.co/Xm9i7aiq85
Abs#1493 #ACR22 @Rheumnow https://t.co/RAGoHeuSIg
Aurelie Najm AurelieRheumo ( View Tweet)
Performance BASDAI & ASDAS in evaluating PsA axial symptoms?
400+ pts DISCOVER 1&2
Weak correlations w/ peripheral arthritis
Moderate/strong correlations w/ fatigue & pain
Both perform similarly but do they perform well enough?
https://t.co/alnrEXtydp
Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK
Aurelie Najm AurelieRheumo ( View Tweet)
Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around). Shame about lack of access to this sequence currently
@RheumNow #ACR22 #osteoporosis https://t.co/S2ttbrVaab
Julian Segan JulianSegan ( View Tweet)
Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiographically + high CRP. Abs 1014 #ACR22 @RheumNow https://t.co/M5Tc0fd64s https://t.co/e25gwVQKeo
Dr. Rachel Tate uptoTate ( View Tweet)
DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI
GUS improves BASDAI, mBASDAI, spinal pain, morning stiffness, and ASDAS from W8 to W24
W24 Response rates BASDAI50 38% BASDAI70 20%
https://t.co/MrS8atrIOI
Abs#1035 #ACR22 @Rheumnow https://t.co/wMDkO1Qak9
Aurelie Najm AurelieRheumo ( View Tweet)
Most important point from the Great Debate on treating pre-RA.
Are we really treating to prevent RA or are we simply delaying RA onset?
I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs.
What would you do?
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
ACPA+ ~40% did not convert to clinical RA
RF+/ACPA+ least likely to seroconvert to negative
@RheumNow #ACR22 https://t.co/djVPKDdWjz
Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Talabi: Progestin-only has⬇️thrombotic risk vs. estrogen👇
‼️Safety signal for DMPA/depo shot bec. might be more prothrombotic vs. other progestin methods; addt'l studies needed; recommend to avoid in aPL+ for now
#ACR22 @Rheumnow https://t.co/pQe5H8wqvi
sheila RHEUMarampa ( View Tweet)
"Less than 1 in 6 rheumatology guideline recommendations are informed by head-to-head RCTs." #ACR22 abst#1284 @rheumnow Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines https://t.co/l5NzzcHRSA
TheDaoIndex KDAO2011 ( View Tweet)
Most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes & Achilles tendon. MEI & MASES best capturing axSpA enthesitis. MEI & SPARCC best in pSpA & PsA. Abs 1004 #ACR22 @RheumNow https://t.co/6IbusqHI5d https://t.co/5y5NFthyJz
Dr. Rachel Tate uptoTate ( View Tweet)
Tofacitinib in new-onset PMR:
Nice mechanistic data - all the right things line up - leading to promising proof-of-concept study (EAST PMR)
Plenty to tease apart here but real promise to explore in bigger studies
ABST1107 #ACR22 @RheumNow https://t.co/s4ts7lrVtZ
David Liew drdavidliew ( View Tweet)
